← Eichor
Condition: Gastric Cancer Stage Ii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gastric Cancer Stage Ii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06774222Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06921928Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
Phase N/A · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06102772Chemoimmunotherapy Followed by Surgery for Oligometastatic Esophagogastric Cancer: (TORO Protocol)
NA · 1 location(s) · University Health Network, Toronto · NCT06668454Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07026149Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fet
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07289997Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA · 2 location(s) · University of California, San Francisco · NCT04221893A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cyto
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05977998Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
Phase 1/Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06759064PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER
Phase 2 · 1 location(s) · Banner Health · NCT07178808DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 · 2 location(s) · Massachusetts General Hospital · NCT07070466A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gast
Phase 2 · 70 location(s) · AstraZeneca · NCT07069712Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer
Phase 2 · 1 location(s) · Fudan University · NCT07517107A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Phase 2 · 1 location(s) · LaNova Medicines Zhejiang Co., Ltd. · NCT05934331Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06572319Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Phase 2 · 1 location(s) · Jeeyun Lee · NCT06630130Reconstruction With a Lawrence-Hunt Jejunal Pouch After Total Gastrectomy
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06967571Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04840264T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT05894824A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Muta
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03190941Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383INTERACT Stomach-II
Phase 2 · 3 location(s) · Erasmus Medical Center · NCT07133490Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
Phase 1/Phase 2 · 1 location(s) · National Health Research Institutes, Taiwan · NCT05927857Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Phase 2 · 1 location(s) · Jinbo Yue · NCT07007182Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer
Phase 3 · 2 location(s) · Ukrainian Society of Clinical Oncology · NCT06755554Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Phase 2 · 4 location(s) · UNICANCER · NCT06846346Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05975749
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.